
Aspira Pathlab & Diagnostics Hits Upper Circuit Amidst Unprecedented Buying Interest
2025-12-02 09:36:27Aspira Pathlab & Diagnostics has witnessed extraordinary buying momentum, hitting the upper circuit with only buy orders in the queue. The stock’s performance today stands out sharply against the broader market, signalling robust investor enthusiasm and the potential for a sustained multi-day circuit scenario.
Read More
Aspira Pathlab & Diagnostics: Analytical Perspective Shifts Amid Mixed Market Signals
2025-12-02 08:59:32Aspira Pathlab & Diagnostics has experienced a revision in its market assessment, reflecting nuanced changes across quality, valuation, financial trends, and technical indicators. This article explores the factors influencing the recent analytical perspective shifts for the healthcare services company, highlighting its financial performance, market behaviour, and technical signals.
Read MoreWhy is Aspira Pathlab falling/rising?
2025-12-02 01:03:15Recent Price Movement and Market Outperformance The stock’s 5.0% gain on the day significantly outpaced its sector peers, outperforming by 5.93%. This marks the third consecutive day of gains, during which Aspira Pathlab has appreciated by 8.49%. Over the past week and month, the stock has delivered returns of 7.97% and 14.87% respectively, far exceeding the Sensex’s modest 0.87% and 2.03% gains in the same periods. Year-to-date, the stock has risen 17.23%, nearly doubling the benchmark’s 9.60% advance. These figures underscore a strong momentum that investors have embraced despite a one-year return of -10.58%, which contrasts with the Sensex’s 7.32% gain. Technical Indicators and Trading Activity Technically, Aspira Pathlab is trading above all...
Read MoreHow has been the historical performance of Aspira Pathlab?
2025-12-01 23:33:21Revenue Growth and Profitability Improvement In the fiscal year ending March 2025, Aspira Pathlab reported consolidated net sales of ₹22.00 crore, marking a significant increase from ₹13.20 crore in the previous year. This growth of approximately 66.7% underscores the company’s expanding market presence and operational scale. Despite no other operating income reported in either year, the total operating income mirrored net sales, reflecting a focused revenue stream. Cost management remained a critical factor in the company’s improved profitability. Raw material costs rose moderately from ₹2.62 crore to ₹3.70 crore, while employee expenses increased from ₹6.20 crore to ₹7.33 crore, consistent with the company’s growth trajectory. Selling and distribution expenses remain...
Read More
Aspira Pathlab & Diagnostics Sees Unprecedented Buying Interest, Edging Towards Multi-Day Upper Circuit
2025-12-01 14:50:36Aspira Pathlab & Diagnostics Ltd has captured the market’s attention with extraordinary buying momentum, registering a 4.98% gain today while the broader Sensex slipped marginally by 0.07%. The stock’s unique position of having only buy orders in the queue signals a potential multi-day upper circuit scenario, underscoring robust investor demand in the healthcare services sector.
Read MoreWhy is Aspira Pathlab falling/rising?
2025-11-19 23:54:24As of 19-Nov, Aspira Pathlab & Diagnostics Ltd is experiencing a price increase, with its current price at Rs 64.20, reflecting a rise of Rs 1.82 or 2.92%. The stock has shown strong performance today, outperforming its sector by 2.26% and achieving a consecutive gain over the last two days, with a total return of 7% during this period. Additionally, the stock reached an intraday high of Rs 65.49, indicating positive momentum. In terms of returns, the stock has increased by 8.72% over the past week, although it has seen a decline of 4.01% over the past month. Notably, the stock's delivery volume has surged by 438.18% compared to the 5-day average, suggesting rising investor participation. There is no information available regarding positive or negative factors that could influence the stock's movement. Broader Market Context: In comparison to the benchmark Sensex, which has gained 0.85% over the past week,...
Read More
Aspira Pathlab & Diagnostics Hits Upper Circuit with Only Buy Orders: A Multi-Day Rally in Sight
2025-11-19 14:21:07Aspira Pathlab & Diagnostics Ltd has witnessed extraordinary buying interest on 19 Nov 2025, hitting the upper circuit with exclusively buy orders in the queue. This rare market phenomenon signals robust demand and the potential for a sustained multi-day circuit scenario, underscoring the stock’s strong momentum in the healthcare services sector.
Read More
Aspira Pathlab Reports Strong Operational Metrics Amid Mixed Stock Performance Trends
2025-11-18 14:01:55Aspira Pathlab & Diagnostics has reported strong financial metrics for the quarter ending September 2025, including record operating cash flow of Rs 1.88 crore and a return on capital employed of 21.54%. Despite these achievements, the company's stock performance has been mixed compared to the Sensex.
Read More
Aspira Pathlab & Diagnostics Ltd Surges 5% Today, Reaching Intraday High of Rs 63
2025-11-18 09:41:38Aspira Pathlab & Diagnostics Ltd is experiencing notable buying activity, with a 5.00% increase today, contrasting with a decline in the Sensex. Despite a challenging month, the stock has shown resilience year-to-date and reached an intraday high of Rs 63, indicating strong buyer interest.
Read MoreCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
07-Jan-2026 | Source : BSECompliance Certificate under reg 74(5) of SEBI (DP) Regulations 2018 for the quarter ended December 31 2025
Announcement under Regulation 30 (LODR)-Newspaper Publication
07-Jan-2026 | Source : BSENewspaper Publication-Postal Ballot
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
06-Jan-2026 | Source : BSEIntimation of Postal Ballot Notice for appointment of Mrs. Kiran Awasthi (DIN:09066721) as an Independent Director for the first term of 5 consecutive years
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available